Press release
Monash University and ClinChoice Forge Strategic Partnership to Accelerate Clinical Development of Innovative Therapies
Monash University and ClinChoice Forge Strategic Partnership
Each organization brings distinct strengths to healthcare innovation, and both share a clear commitment to improving health and wellbeing for patients around the world.
Monash is a top 50 global university, and is Australia's largest university with a global presence across the Indo-Pacific, Europe and the US.
The University is also part of Australia's largest clinical trial network, spanning five major affiliated health services with more than 7,000 hospital beds and a national network of more than 3,000 GPs. Monash University-led trials account for around a quarter of all clinical trial activity in Australia, reaching a patient population of 4.5 million people.
The collaboration combines Monash University's internationally recognized research excellence and clinical ecosystem with ClinChoice's global development, regulatory
and data science capabilities to support high‐quality, patient‐centric research across Australia and the broader international research landscape. A particular focus will be on accelerating early-phase clinical development and bringing innovative therapies to patients faster.
"Monash is deeply committed to pursuing impact-driven partnerships that leverage our expertise in research and healthcare innovation," said Professor Robyn Ward AM, Deputy Vice-Chancellor (Research and Enterprise). "We're proud to partner with ClinChoice. By combining our research excellence with their global capability, we can bring new therapies and technologies to patients while strengthening collaboration between our talented researchers with the global biotechnology sector."
"We are honored to formalize this partnership with Monash University, a globally respected institution at the forefront of pharmaceutical science," said Kevin Xu, Chairman and CEO of ClinChoice, "This collaboration is a strong testament to ClinChoice's mission to support innovation through academic and clinical partnerships."
"By combining our global development experience with Monash's research excellence, we will advance clinical research in an even more efficient and impactful manner, ultimately bringing new therapies to patients faster," added Kerry Dyson, President, International Clinical Operations at ClinChoice.
About Monash University
Monash University is one of Australia's premier research-intensive universities and a globally recognized leader in pharmaceutical sciences and pharmacology.
The university ranks in the world's top-50 universities in the QS World University Rankings 2026, QS Sustainability Rankings 2026 and US News and World Report (USNWR) Best Global Universities Rankings 2025-26. Monash has an international reputation for excellence in healthcare research and translation, and is ranked third internationally in Pharmacy and Pharmaceutical Sciences and fourth in Pharmacy and Pharmacology.
Through its world-renowned Monash Institute of Pharmaceutical Sciences (MIPS), Monash drives breakthrough innovations from target identification through preclinical and translational development.
Consistently ranking among the top institutions worldwide for pharmacy and pharmacology, Monash plays a pivotal role in advancing novel therapeutics by integrating fundamental science with strong industry collaboration to translate research into real-world healthcare outcomes.
The university is home to the Monash Technology Precinct, bringing together researchers, industry partners and world-class facilities to drive collaboration and innovation - creating commercial opportunities and delivering meaningful benefits for communities.
300 Welsh Road
Building 5, Suite 201
Horsham, PA 19044
USA
About ClinChoice
ClinChoice a global, clinical-stage CRO partnering with pharmaceutical and biotechnology companies to translate scientific innovation into clinical impact. With more than 30 years of experience and operations spanning over 15 countries across North America, Europe and Indo/Asia-Pacific, ClinChoice brings deep therapeutic expertise in hematology/oncology, immunology and inflammation (I&I), cardiometabolics and CNS. Having delivered more than 3,000 studies globally,
ClinChoice has a strong track record of working with biopharmaceutical companies worldwide, and delivering early phase as well as late stage programs with speed, quality and innovation.
Read the Full Release: https://clinchoice.com/monash-university-and-clinchoice-forge-strategic-partnership-to-accelerate-clinical-development-of-innovative-therapies/
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Monash University and ClinChoice Forge Strategic Partnership to Accelerate Clinical Development of Innovative Therapies here
News-ID: 4447674 • Views: …
More Releases from ClinChoice Inc.
ClinChoice Earns Global ISO 9001:2015 and ISO 14155:2020 Re-Certification by TU …
ClinChoice is proud to announce the successful completion and approval of its ISO 9001:2015 and ISO 14155:2020 Re-Certification by TÜV NORD.
The audit, conducted between 13 October 2025 and 4 November 2025, spanned our United States, Italy, Philippines, Armenia, and India delivery sites. The comprehensive assessment involved nine auditors and approximately 20 man-days of rigorous evaluation.
This achievement marks a significant milestone in our quality journey - the consolidation of our Quality…
Going Beyond the Missing: An Approach to Handling Dropouts in Longitudinal Clini …
In longitudinal clinical trials, missing data is a threat to scientific integrity. Whether due to patient dropouts, missed visits, or protocol deviations, these gaps can distort results, reduce statistical power, and invite regulatory scrutiny. With dropout rates averaging around 3-8% for the last three years, the stakes are high. As the industry continues to evolve, so should the strategies we implement.
The Fall of Traditional Fixes
For years, researchers have relied on…
Proactive vs. Reactive Monitoring: Preventing Common Clinical Trial Site Errors
In today's clinical trial landscape, defined by compressed timelines, complex protocols, and global decentralization, site execution remains one of the most vulnerable points in study success. Despite technological innovation, sponsor oversight is often still hindered by a lingering reliance on outdated, reactive monitoring models. The issue isn't site incompetence. It's the monitoring strategy.
Reasons Why Traditional Monitoring Falls Short
Conventional monitoring practices, centered on periodic on-site visits and source data verification, struggle…
More Releases for Monash
IVF Center Market Is Going to Boom | Major Giants IVI RMA Global, Virtus Health, …
HTF MI just released the Global IVF Center Market Study, a comprehensive analysis of the market that spans more than 143+ pages and describes the product and industry scope as well as the market prognosis and status for 2024-2033. The marketization process is being accelerated by the market study's segmentation by important regions. The market is currently expanding its reach.
Major companies profiled in IVF Center Market are: IVI RMA Global,…
IVF Services Market Set for Explosive Growth | Nova IVF, Boston IVF, Monash IVF
HTF MI recently introduced Global IVF Services Market study with 143+ pages in-depth overview, describing about the Product / Industry Scope and elaborates market outlook and status (2024-2032). The market Study is segmented by key regions which is accelerating the marketization. At present, the market is developing its presence. Some key players from the complete study are Virtus Health, Monash IVF, Care Fertility, Apollo Hospitals, Boston IVF, CooperSurgical, Genea Biomedx,…
Fertility Services Market Is Booming So Rapidly | Ferring, Dohme, Monash
The Global Fertility Services Market Size is estimated to register 14.2% growth over the forecast period from 2023 to 2030.
The latest study released on the Global Fertility Services Market by USD Analytics Market Research evaluates market size, trend, and forecast to 2030. The Fertility Services market study covers significant research data and proofs to be a handy resource document for managers, analysts, industry experts and other key people to have…
Ethnolink inspires Monash University’s next generation of translators
Yesterday, our team at Ethnolink spoke to Monash University’s Masters of Interpreting and Translation Studies students.
Among those who spoke at the presentation were our CEO, Costa Vasili, and multicultural communications experts from across all branches of our organisation, Cloe, Rachael, and Bethany.
Each member of our presentation team comes from different language backgrounds and has a different role within our company. As such, they each have their own unique perspective on…
Global Fertility Services Market 2020 Business Strategies – CooperSurgicalInc. …
The Zion Market Research added a new report “Fertility Services Market: by Procedure (Assisted Reproductive Technology (ART), In-Vitro Fertilization, Artificial Insemination, Surrogacy, and Others); by Service (Donor and Non-donor); and by End-User (Fertility Clinics, Hospitals, and Clinical Research Institutes): Global Industry Perspective, Comprehensive Analysis and Forecast, 2018 - 2024” in its database, which provides an expert and in-depth analysis of key business trends and future market development prospects, key drivers…
Coal to Liquid Market SWOT Analysis by Leading Key Players- Yankuang, DKRW Energ …
HTF MI recently introduced Global Coal to Liquid (CTL) Market study with in-depth overview, describing about the Product / Industry Scope and elaborates market outlook and status to 2023. The market Study is segmented by key regions which is accelerating the marketization. At present, the market is developing its presence and some of the key players from the complete study are Pall, Shenhua, Yankuang, DKRW Energy, Bumi, Monash Energy &…
